PolyPid reports Q3 2026 results, D-PLEX100 FDA review on track for November 28 PDUFA date
PolyPid says labeling talks with FDA are proceeding on schedule, Azurity is readying a U.S. launch, and PolyPid has regained European commercial rights to D-PLEX100.
SEC filing